Source:http://linkedlifedata.com/resource/pubmed/id/17382968
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
21
|
pubmed:dateCreated |
2007-4-23
|
pubmed:abstractText |
Nodakenin is a coumarin compound initially isolated from the roots of Angelica gigas. In the present study, we investigated the effects of nodakenin on learning and memory impairments induced by scopolamine (1 mg/kg, i.p.) using the passive avoidance test, the Y-maze test, and the Morris water maze test in mice. Nodakenin (10 mg/kg, p.o.) administration significantly reversed scopolamine-induced cognitive impairments in the passive avoidance test and the Y-maze test (P<0.05), and also reduced escape latency during training in the Morris water maze test (P<0.05). Moreover, swimming times and distances within the target zone of the Morris water maze were greater in the nodakenin-treated group than in the scopolamine-treated group (P<0.05). In an in vitro study, nodakenin was found to inhibit acetylcholinesterase activity in a dose-dependent manner (IC(50)=84.7 microM). In addition, nodakenin was also found to inhibit acetylcholinesterase activity for 6 h in an ex-vivo study. These results suggest that nodakenin may be a useful for the treatment of cognitive impairment, and that its beneficial effects are mediated, in part, via the enhancement of cholinergic signaling.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholinesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Coumarins,
http://linkedlifedata.com/resource/pubmed/chemical/Glucosides,
http://linkedlifedata.com/resource/pubmed/chemical/Scopolamine Hydrobromide,
http://linkedlifedata.com/resource/pubmed/chemical/nodakenin
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0024-3205
|
pubmed:author |
pubmed-author:CheongJae HoonJH,
pubmed-author:JungJi WookJW,
pubmed-author:KangSam SikSS,
pubmed-author:KimDo Yoondo Y,
pubmed-author:KimDong HyunDH,
pubmed-author:KimYeong ShikYS,
pubmed-author:KimYoung ChoongYC,
pubmed-author:KoKwang HoKH,
pubmed-author:LeeSeungjooS,
pubmed-author:RyuJong HoonJH,
pubmed-author:YoonByung HoonBH
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1944-50
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:17382968-Analysis of Variance,
pubmed-meshheading:17382968-Animals,
pubmed-meshheading:17382968-Cholinesterase Inhibitors,
pubmed-meshheading:17382968-Coumarins,
pubmed-meshheading:17382968-Dose-Response Relationship, Drug,
pubmed-meshheading:17382968-Escape Reaction,
pubmed-meshheading:17382968-Glucosides,
pubmed-meshheading:17382968-Male,
pubmed-meshheading:17382968-Maze Learning,
pubmed-meshheading:17382968-Memory Disorders,
pubmed-meshheading:17382968-Mice,
pubmed-meshheading:17382968-Mice, Inbred ICR,
pubmed-meshheading:17382968-Molecular Structure,
pubmed-meshheading:17382968-Scopolamine Hydrobromide
|
pubmed:year |
2007
|
pubmed:articleTitle |
Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice.
|
pubmed:affiliation |
Department of Oriental Pharmaceutical Science and East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, Hoeki-dong, Dongdaemoon-Ku, Seoul 130-701, Republic of Korea.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|